Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Oragenics Inc (OGEN) Common Stock USD0.001

Sell:$0.50 Buy:$0.54 Change: $0.0113 (2.13%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$0.50
Buy:$0.54
Change: $0.0113 (2.13%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
Sell:$0.50
Buy:$0.54
Change: $0.0113 (2.13%)
Market closed |  Prices as at close on 12 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models.

Contact details

Address:
4902 Eisenhower Blvd Ste 125
TAMPA
33634-6342
United States
Telephone:
+1 (813) 2867900
Website:
https://www.oragenics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OGEN
ISIN:
US6840233026
Market cap:
$25.75 million
Shares in issue:
46.12 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Frederick Telling
    Independent Chairman of the Board
  • Alan Joslyn
    President, Chief Executive Officer, Director
  • Michael Sullivan
    Chief Financial Officer, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.